Literature DB >> 33536051

Diagnostic and severity scores for Cockayne syndrome.

M A Spitz1, F Severac2,3, C Obringer4, S Baer1, N Le May4, N Calmels5, V Laugel6,7.   

Abstract

BACKGROUND: Cockayne syndrome is a progressive multisystem genetic disorder linked to defective DNA repair and transcription. This rare condition encompasses a very wide spectrum of clinical severity levels ranging from severe prenatal onset to mild adult-onset subtypes. The rarity, complexity and variability of the disease make early diagnosis and severity assessment difficult. Based on similar approaches in other neurodegenerative disorders, we propose to validate diagnostic and severity scores for Cockayne syndrome.
METHODS: Clinical, imaging and genetic data were retrospectively collected from 69 molecularly confirmed CS patients. A clinical diagnostic score and a clinical-radiological diagnostic score for CS were built using a multivariable logistic regression model with a stepwise variable selection procedure. A severity score for CS was designed on five items (head circumference, growth failure, neurosensorial signs, motor autonomy, communication skills) and validated by comparison with classical predefined severity subtypes of CS.
RESULTS: Short stature, enophtalmos, hearing loss, cataracts, cutaneous photosensitivity, frequent dental caries, enamel hypoplasia, morphological abnormalities of the teeth, areflexia and spasticity were included in the clinical diagnostic score as being the most statistically relevant criteria. Appropriate weights and thresholds were assigned to obtain optimal sensitivity and specificity (95.7% and 86.4% respectively). The severity score was shown to be able to quantitatively differentiate classical predefined subtypes of CS and confirmed the continuous distribution of the clinical presentations in CS. Longitudinal follow-up of the severity score was able to reflect the natural course of the disease.
CONCLUSION: The diagnostic and severity scores for CS will facilitate early diagnosis and longitudinal evaluation of future therapeutic interventions. Prospective studies will be needed to confirm these findings.

Entities:  

Keywords:  Clinical severity; Cockayne syndrome; Diagnosis; Score

Mesh:

Year:  2021        PMID: 33536051      PMCID: PMC7860636          DOI: 10.1186/s13023-021-01686-8

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  25 in total

1.  A comprehensive description of the severity groups in Cockayne syndrome.

Authors:  Valerie Natale
Journal:  Am J Med Genet A       Date:  2011-04-07       Impact factor: 2.802

2.  A clinical rating scale for Batten disease: reliable and relevant for clinical trials.

Authors:  F J Marshall; E A de Blieck; J W Mink; L Dure; H Adams; S Messing; P G Rothberg; E Levy; T McDonough; J DeYoung; M Wang; D Ramirez-Montealegre; J M Kwon; D A Pearce
Journal:  Neurology       Date:  2005-07-26       Impact factor: 9.910

3.  The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH.

Authors:  K A Henning; L Li; N Iyer; L D McDaniel; M S Reagan; R Legerski; R A Schultz; M Stefanini; A R Lehmann; L V Mayne; E C Friedberg
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

4.  Study of Intraventricular Cerliponase Alfa for CLN2 Disease.

Authors:  Angela Schulz; Temitayo Ajayi; Nicola Specchio; Emily de Los Reyes; Paul Gissen; Douglas Ballon; Jonathan P Dyke; Heather Cahan; Peter Slasor; David Jacoby; Alfried Kohlschütter
Journal:  N Engl J Med       Date:  2018-04-24       Impact factor: 91.245

Review 5.  Cockayne syndrome and xeroderma pigmentosum.

Authors:  I Rapin; Y Lindenbaum; D W Dickson; K H Kraemer; J H Robbins
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

6.  Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.

Authors:  Bram De Wel; Veerle Goosens; Atka Sobota; Elke Van Camp; Ellen Geukens; Griet Van Kerschaver; Marlène Jagut; Kathleen Claes; Kristl G Claeys
Journal:  J Neurol       Date:  2020-09-15       Impact factor: 4.849

7.  Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update.

Authors:  Marc C Patterson; Christian J Hendriksz; Mark Walterfang; Frederic Sedel; Marie T Vanier; Frits Wijburg
Journal:  Mol Genet Metab       Date:  2012-05-08       Impact factor: 4.797

8.  The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care.

Authors:  Brian T Wilson; Zornitza Stark; Ruth E Sutton; Sumita Danda; Alka V Ekbote; Solaf M Elsayed; Louise Gibson; Judith A Goodship; Andrew P Jackson; Wee Teik Keng; Mary D King; Emma McCann; Toshino Motojima; Jennifer E Murray; Taku Omata; Daniela Pilz; Kate Pope; Katsuo Sugita; Susan M White; Ian J Wilson
Journal:  Genet Med       Date:  2015-07-23       Impact factor: 8.822

9.  Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.

Authors:  Francesco Muntoni; Joana Domingos; Adnan Y Manzur; Anna Mayhew; Michela Guglieri; Gautam Sajeev; James Signorovitch; Susan J Ward
Journal:  PLoS One       Date:  2019-09-03       Impact factor: 3.240

10.  Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.

Authors:  Jerry R Mendell; Zarife Sahenk; Kelly Lehman; Carrie Nease; Linda P Lowes; Natalie F Miller; Megan A Iammarino; Lindsay N Alfano; Amanda Nicholl; Samiah Al-Zaidy; Sarah Lewis; Kathleen Church; Richard Shell; Linda H Cripe; Rachael A Potter; Danielle A Griffin; Eric Pozsgai; Ashish Dugar; Mark Hogan; Louise R Rodino-Klapac
Journal:  JAMA Neurol       Date:  2020-09-01       Impact factor: 18.302

View more
  4 in total

1.  Statistical Approach of the Role of the Conserved CSB-PiggyBac Transposase Fusion Protein (CSB-PGBD3) in Genotype-Phenotype Correlation in Cockayne Syndrome Type B.

Authors:  Rayanne Damaj-Fourcade; Nicolas Meyer; Cathy Obringer; Nicolas Le May; Nadège Calmels; Vincent Laugel
Journal:  Front Genet       Date:  2022-02-17       Impact factor: 4.599

2.  Heterogeneous clinical features in Cockayne syndrome patients and siblings carrying the same CSA mutations.

Authors:  Asma Chikhaoui; Ichraf Kraoua; Nadège Calmels; Sami Bouchoucha; Cathy Obringer; Khouloud Zayoud; Benjamin Montagne; Ridha M'rad; Sonia Abdelhak; Vincent Laugel; Miria Ricchetti; Ilhem Turki; Houda Yacoub-Youssef
Journal:  Orphanet J Rare Dis       Date:  2022-03-05       Impact factor: 4.123

3.  Cockayne syndrome without UV-sensitivity in Vietnamese siblings with novel ERCC8 variants.

Authors:  Nguyen Thuy Duong; Tran Huu Dinh; Britta S Möhl; Stefan Hintze; Do Hai Quynh; Duong Thi Thu Ha; Ngo Diem Ngoc; Vu Chi Dung; Noriko Miyake; Nong Van Hai; Naomichi Matsumoto; Peter Meinke
Journal:  Aging (Albany NY)       Date:  2022-06-22       Impact factor: 5.955

4.  Cockayne Syndrome-Associated CSA and CSB Mutations Impair Ribosome Biogenesis, Ribosomal Protein Stability, and Global Protein Folding.

Authors:  Mingyue Qiang; Fatima Khalid; Tamara Phan; Christina Ludwig; Karin Scharffetter-Kochanek; Sebastian Iben
Journal:  Cells       Date:  2021-06-28       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.